A Study of How Proton Beam Radiotherapy (PBRT) Affects Brain Function and Quality of Life in Children and Young Adults Undergoing Treatment for a Brain Tumor

NCT ID: NCT05288439

Last Updated: 2026-01-12

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-03-07
• Study Completion Date: 2027-03-31

Brief Summary

The researchers are doing this study to find out if there are differences in the resting state brain networks of children and young adults (ages 6-25) after treatment with proton beam radiation therapy (PBRT). The researchers will use resting state functional connectivity magnetic resonance imagining (rs-fcMRI) scanning to detect these differences. The researchers will also check for differences in participants' thinking and quality of life through a cognitive assessment and a questionnaire. Both people undergoing PBRT for a brain tumor and healthy people will take part in this study so that the researchers can compare the brain networks (connections in the brain that are involved in certain function, such as memory or attention), thinking patterns, and quality of life of these two groups of participants.

The study researchers think that rs-fcMRI scans may be an effective way to look at the brain networks after treatment with PBRT and see if this treatment causes differences in those networks, including damage to the brain (neurotoxicity). rs-fcMRI scans take images when a patient is in a resting state, which means the patient is not performing a task or thinking about anything in particular.

This study will provide valuable information about how PBRT affects brain networks, thinking (cognitive) abilities, and quality of life in children and young adults. The study results may have an impact on future treatment approaches for brain cancer and the use of PBRT in children and young adults.

Conditions

Brain Tumor; Metastatic Brain Tumor

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

patients

A full neurocognitive battery with quality-of-life assessment will be conducted and an rs-fcMRI sequence will be added to the brain MRI performed as standard of care follow-up between 3-5 months post-PBRT.

Group Type: EXPERIMENTAL

Resting-state functional connectivity MRI

Intervention Type: DIAGNOSTIC_TEST

participants will undergo functional MRI

Neurocognitive battery with quality-of-life assessment

Intervention Type: OTHER

Cognitive and quality of life assessments performed by a trained neuropsychologist

healthy matched controls

Healthy participants will be asked to complete the MRI scan and undergo neurocognitive assessment.

Group Type: EXPERIMENTAL

Resting-state functional connectivity MRI

Intervention Type: DIAGNOSTIC_TEST

participants will undergo functional MRI

Neurocognitive battery with quality-of-life assessment

Intervention Type: OTHER

Cognitive and quality of life assessments performed by a trained neuropsychologist

Interventions

Resting-state functional connectivity MRI

participants will undergo functional MRI

Intervention Type: DIAGNOSTIC_TEST

Neurocognitive battery with quality-of-life assessment

Cognitive and quality of life assessments performed by a trained neuropsychologist

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

Patients Treated for Brain Tumors:

• The patient has been diagnosed with a primary or metastatic brain tumor
• The patient has been recommended to receive cranial PBRT for a primary or metastatic brain tumor
• The patient is between the ages of 6 through 25 at time of consent
• As per medical record or patient report (based on prior tolerance of MRI), the participant is able to tolerate MRI without sedation (i.e., general anesthesia). Patients will take medications as prescribed or directed by the patient's physician. If in accordance with their prescribed regimen, agents that may impact the CNS, such as benzodiazepines and/or antihistamines, should be avoided on the day of imaging and neurocognitive assessment.

Healthy Control Participants:

• The control has no major medical illness, as determined by medical interview by study physician
• As per parent report, the control is between the ages of 6 through 25 at time of consent
• As per parent report, the control is able to tolerate an MRI without sedation (i.e., general anesthesia). Participants should only take medications as prescribed or directed by their physician. They should not take additional medications, such as antihistamines, for the purpose of tolerating MR imaging.

Exclusion Criteria

• As per self or parent report, the participant has completed any portion of the neuropsychological battery used in this study within the last year.
• As per medical record or self or parent report, there is an existing diagnosis of intellectual disability and/or prior IQ testing that documents Full Scale IQ standard score <70 at baseline.
• As per medical record, there is an existing diagnosis of psychiatric disorder or untreated mood disturbance, prior stroke or intracranial hemorrhage, or neurodegenerative disease.
• The participant has an MRI contraindication (e.g., implanted ferromagnetic devices, claustrophobia) as per radiology clinical operating procedures.
• As per self or parent report, non-fluency in English language as demonstrated by current educational placement in a non-English-speaking classroom setting.

• Minimum Eligible Age: 6 Years
• Maximum Eligible Age: 25 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Memorial Sloan Kettering Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Andrei Holodny, MD

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Locations

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Countries

United States

Related Links

http://www.mskcc.org/mskcc/html/44.cfm

Memorial Sloan Kettering Cancer Center

Other Identifiers

22-061

Identifier Type: -

Identifier Source: org_study_id